CTOs on the Move

Anagenex

www.anagenex.com

 
Discovering new medicines by combining ultra throughput biochemistry and machine learning.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Adrian Schreyer
Chief Technology Officer Profile

Funding

Anagenex raised $30M on 06/08/2022

Similar Companies

Cadent Therapeutics

Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease.

Ohana Biosciences

Ohana is pioneering a new frontier in reproductive medicine. Built upon a world-leading understanding of sperm biology, Ohana has created a best-in-class proprietary platform with broad applications across reproductive medicine.

Pharmathene

Pharmathene, Inc is a Annapolis, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cue Health

Cue Health is a health technology company that develops and manufactures portable, compact, connected medical diagnostic products that help people, organizations, and communities protect human health. Headquartered in San Diego, California, our mission is to empower healthcare providers and organizations by increasing their access to rapid, accurate, actionable health data in real-time. We have built a culture that is dynamic, innovative, and results-oriented. We seek driven and talented individuals to join our multi-disciplinary engineering, regulatory, clinical, operations, production, and testing teams. If you`re ready to help us reinvent the future of healthcare, reach out to us today.

Genprex

Genprex (Nasdaq: GNPX) is a clinical-stage gene therapy company focused on developing life-changing technologies for patients with cancer and diabetes. Genprex`s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases.